Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Journal article published in 2020 by
C. P. Cannon,
Perkovic,
R. Agarwal,
J. Baldassarre,
G. Bakris,
D. M. Charytan,
D. de Zeeuw,
R. Edwards,
T. Greene 
,
H. J. L. Heerspink,
M. J. Jardine,
A. Levin,
J.-W. Li,
B. Neal,
C. Pollock
and other authors.
,
H. J. L. Heerspink,
M. J. Jardine,
A. Levin,
J.-W. Li,
B. Neal,
C. Pollock
and other authors.
